This is a list of all Oncology related medical scores and algorithms with their corresponding calculator/app.
These are the Collin et al. and Shah et al. modifications to the original Barthel Index that assesses functional disability based on 10 activities of daily life (ADLs).
Uses tumor grade and lymphatic characteristics to determine the risk of malignancy recurrence.
Predicts survival rate in patients with aggressive non-Hodgkin’s lymphoma.
Uses independent prognostic factors such as LDH, ECOG score or leukocyte count to stratify malignancy risk.
Predicts survival in patients with metastatic renal cell carcinoma.
Prognoses outcome and risk of complications in patients with cancer who undergo chemotherapy.
Predicts survival in patients with chronic myeloid leukemia (CML) based on spleen size, platelet count and myeloblast percentage.
Evaluates the cancer patient’s ability to undergo chemotherapy.
Assesses functional disability by quantifying patient performance in 10 activities of daily life (ADLs).
Helps diagnose MM based on blood and bone marrow characteristics.
Determines survival rate for patients suffering from follicular lymphoma and adverse outcome factors.
Stratifies the type of cancer according to the CAPRA score including age, Gleason score and PSA.
Evaluates the functional status of patients with cancer to determine their prognosis.
Determines prostate tumor volume and density to help with differential diagnosis between benign prostatic hyperplasia (BPH) and prostate cancer.
Assesses stage and prognosis of prostate neoplasm based on biopsy findings.
Determines absolute and relative washout based on pre and post contrast and 15 minutes delayed CT scans.
Determines prostate neoplasm recurrence based on PSA, Gleason score and cancer stage.
Predicts 2-year survival rates for patients with small cell lung cancer (SCLC) based on Karnofsky score and lab tests.
Diagnoses benign versus malignant thyroid nodules based on ultrasound findings.
Determines the biologically effective dose (BED) and the equivalent dose (EQD2) for cancer radiotherapy.
Stratifies VTE risk in cancer patients due to start chemotherapy.
Evaluates CRS severity in patients receiving immunotherapy for cancer.
Helps distinguish between adenomas and malignant tumors based on quantitative signal measurements.
Screens for fracture risk in patients with long bone metastasis based on criteria for prophylactic fixation.
Predicts likelihood of cancer of the evaluated lung nodules in the next 2 to 4 years.
Evaluates recurrence and progression of a non-muscle invasive bladder malignancy over one and five years.
Classifies ovarian cancer based on tumor location, size, grade and lymph nodes or metastatic spread.